ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Pharmaceutical
The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on June 4, with more than 2,500 abstract presentations representing cutting-edge research from around the world. 28 May 2021
Biotechnology
The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency’s Priority Review scheme, with a decision expected by November 29. 27 May 2021
Biotechnology
US pharma major Merck & Co’s presentations at this year’s ASCO annual meeting will focus primarily on three products. 25 May 2021
Biotechnology
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai’s Junshi Biosciences to shine. 25 May 2021
Pharmaceutical
While UK-based drugmaker AstraZeneca has mostly made headlines of late for its development of a coronavirus vaccine, the firm’s work in oncology is potentially of greater significance. 25 May 2021
Biotechnology
Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 ASCO Annual Meeting. 25 May 2021
Biotechnology
Last week, US biotech Sarepta Therapeutics impressed with early-stage data on SRP-9001, a gene therapy candidate for Duchenne muscular dystrophy under development with Roche. GlaxoSmithKline reported positive results from a Phase II trial of a plant-based COVID-19 vaccine being developed with Medicago. Ahead of the American Society of Clinical Oncology (ASCO) meeting next month, Bristol Myers Squibb last Wednesday outlined its planned presentations, with a strong focus on its next-generation checkpoint blocker relatlimab, which has implications for Immutep. Also, Eli Lilly released new data on tirzepatide compared to insulin glargine in type 2 diabetes patients. 23 May 2021
Biotechnology
At this year’s ASCO meeting, Bristol Myers Squibb will present the first data from a Phase III trial evaluating a LAG-3-blocking antibody. 20 May 2021
Biotechnology
In a Special Report, Mircea Cubillos, Regional Commercial Strategy Leader, Haematology, Janssen EMEA, reflects on the recent ASCO and EHA congresses. And despite the unprecedented virtual format, he claims the oncology community can come away from both events feeling excited about the future. 24 June 2020
Pharmaceutical
French pharma major Sanofi has set out its four-pronged plan for oncology blockbusters. 4 June 2020
Biotechnology
Regeneron and Sanofi have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. 1 June 2020
Biotechnology
Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically-meaningful overall survival (OS) benefit as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 1 June 2020
Biotechnology
Detailed results from the Phase III ADAURA trial released for the first time showed that Tagrisso (osimertinib) demonstrated a statistically-significant and clinically-meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. 29 May 2020
Biotechnology
New data in bladder cancer could help make Bavencio (avelumab) more than just an also ran in checkpoint inhibition. 29 May 2020
Pharmaceutical
Swiss pharma major Novartis has announced a new exploratory subgroup analysis from the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20 Virtual Scientific Program. 27 May 2020
Pharmaceutical
At this year’s ASCO, positive Phase III data for Erleada (apalutamide) in prostate cancer will boost prescriber confidence in the therapy, building on datasets presented at last year’s event. 14 May 2020
Biotechnology
Ahead of featuring the data at the American Society of Clinical Oncology (ASCO) meeting later this month, results from the Phase III CheckMate-9LA trial, which demonstrated a statistically-significant and clinically-meaningful survival benefit with Opdivo (nivolumab) plus Yervoy (ipilimumab), given concomitantly with two cycles of chemotherapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC), have been released. 14 May 2020
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
Biotechnology
The headline-grabbing results on AMG 510, the first KRASG12C inhibitor to reach the clinical stage, were not the only data to be shared by US biotech Amgen on its early-stage oncology pipeline. 5 June 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze